About Entegrion
Entegrion is a company based in Durham (United States) founded in 2002. Entegrion has raised $30.45 million across 14 funding rounds from investors including ONR and U.S. Department of Defense. The company has 4 employees as of December 31, 2020. Entegrion offers products and services including VCM. Entegrion operates in a competitive market with competitors including Accriva Diagnostics, Diagnostica Stago, Enzyre, MedicQuant ApS and Perosphere, among others.
- Headquarter Durham, United States
- Employees 4 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Entegrion, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30.45 M (USD)
in 14 rounds
-
Latest Funding Round
$13.87 M (USD), Series B
Jul 05, 2022
-
Investors
ONR
& 1 more
-
Employee Count
4
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Entegrion
Entegrion offers a comprehensive portfolio of products and services, including VCM.
Portable system for rapid blood coagulation testing and hemostasis.
People of Entegrion
Unlock access to complete
Unlock access to complete
Funding Insights of Entegrion
Entegrion has successfully raised a total of $30.45M across 14 strategic funding rounds. The most recent funding activity was a Series B round of $13.87 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Entegrion
Entegrion has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include ONR and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Military forces are provided by the U.S. Department of Defense for national security.
|
Locked | Locked | Locked |
Investor details for Entegrion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Entegrion
Investment portfolio details for Entegrion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Entegrion
Detailed financials for Entegrion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Entegrion Comparisons
Peer comparison for Entegrion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Entegrion
Entegrion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accriva Diagnostics, Diagnostica Stago, Enzyre, MedicQuant ApS and Perosphere, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Near-patient diagnostic systems for coagulation testing are developed.
|
|
| Locked | Locked | Locked |
A portfolio of hemostasis and coagulation diagnostic products is manufactured.
|
|
| Locked | Locked | Locked |
Smart diagnostics devices for blood coagulation analysis are developed.
|
|
| Locked | Locked | Locked |
Diagnostic kits for blood anticoagulant detection are provided.
|
|
| Locked | Locked | Locked |
Anticoagulant reversal agent and small molecules to prevent allergic reactions, traumatic brain injury.
|
Detailed competitors of Entegrion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Entegrion
Complete news archive for Entegrion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Entegrion
Entegrion was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Entegrion is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
John Mowell is the current CEO of Entegrion.
Entegrion is a funded company, having raised a total of $30.45M across 14 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Entegrion is 4.
Entegrion was founded in 2002 in Durham, United States, and operates in the medical devices sector. Hemostasis and fluid replacement products are developed, including the Portable Coagulation Monitor based on Thromboelastography for emergency medicine, obstetrics, and surgery. Additional offerings encompass Multi-Functional Resuscitation Fluid, hemostatic patches, and Stasix particles for targeted vascular delivery. Operations focus on pre-hospital and clinical settings.
Entegrion's top competitors include Accriva Diagnostics, Diagnostica Stago and MedicQuant ApS.
Entegrion offers VCM.
Entegrion has 2 investors. Key investors include ONR, and U.S. Department of Defense.